

HHS Public Access

Clin Transplant. Author manuscript; available in PMC 2019 September 01.

Published in final edited form as:

Author manuscript

Clin Transplant. 2018 September; 32(9): e13353. doi:10.1111/ctr.13353.

Report from the American Society of Transplantation Psychosocial Community of Practice Adherence Task Force: Real-world options for promoting adherence in adult recipients

Larissa Myaskovsky¹, Michelle T. Jesse², Kristin Kuntz³, Abbie D. Leino⁴, John Devin Peipert⁵, Cynthia L. Russell⁶, Christina A. Spivey⁷, Nimisha Sulejmani⁸, and Mary Amanda Dew⁹

¹Center for Healthcare Equity in Kidney Disease and Department of Internal Medicine, School of Medicine, University of New Mexico, Albuquerque, New Mexico

²Transplant Institute, Henry Ford Health System, Detroit, Michigan

³Department of Psychiatry and Behavioral Health, The Ohio State University Wexner Medical Center, Columbus, Ohio

⁴Transplant Center, The Ohio State University Wexner Medical Center, Columbus, Ohio

⁵Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois

⁶School of Nursing and Health Studies, University of Missouri, Kansas City, Missouri

⁷Department of Clinical Pharmacy, University of Tennessee Health Science Center, Memphis, Tennessee

⁸Department of Pharmacy, Henry Ford Hospital, Detroit, Michigan

⁹Departments of Psychiatry, Psychology, Epidemiology and Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania

Abstract

Starting in 2015, the American Society of Transplantation Psychosocial Community of Practice, with representatives of the Transplant Pharmacy Community of Practice, convened a taskforce to develop a white paper that focused on clinically practical, evidenced-based interventions that transplant centers could implement to increase adherence to medication and behavioral recommendations in adult solid organ transplant recipients. The group focused on what centers could do in their daily routines to implement best practices to increase adherence in adult transplant recipients. We developed a list of strategies using available resources, clinically feasible methods of screening and tracking adherence, and activities that ultimately empower patients to improve their own self-management. We limited the target population to adults because they

Correspondence: Larissa Myaskovsky, PhD, Department of Internal Medicine, MSC10-5550, University of New Mexico, Albuquerque, New Mexico 87131 (Imyaskovsky@salud.unm.edu).

This article is a work product of the American Society of Transplantation's Psychosocial Community of Practice. CONFLICT OF INTEREST None.

predominate the research, and because adherence issues differ in pediatric patients, given the necessary involvement of parents/guardians. We also examined broader multilevel areas for intervention including provider and transplant program practices. Ultimately, the task force aims to foster greater recognition, discussion, and solutions required for implementing practical interventions targeted at improving adherence.

Keywords

adherence; adult recipients; organ transplantation

1 | INTRODUCTION

Adherence, dynamic and multifaceted, is "the extent to which a person's behavior – taking medication, following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health care provider."¹ The World Health Organization outlines five overarching dimensions or factors that impact adherence, including the following: health system/healthcare team, social/economic, condition-related, therapy-related, and patient-related.¹ Despite challenges patients may face in these dimensions, it is recommended that individuals living with a solid organ transplant maintain adherence for successful clinical outcomes.

Meta-analytic findings show that, on average, 23 per 100 organ transplant patients per year are nonadherent with immunosuppressant medications,² and that nonadherence to the medical regimen increases with time post-transplant.² Patients may have occasional or intermittent lapses in adherence, variability in immunosuppression exposure, or differences in immunologic risk; thus, the clinical outcomes of nonadherence vary.³ Nonadherence has been associated with acute rejection, post-transplant infections, decreased graft survival, increased medical costs, and overall mortality.⁴ Given the potential for serious adverse outcomes, a multimodal approach to post-transplant adherence, including assessment for identifying nonadherence, education for patients and caregivers, and multilevel systematic evaluation and improvement strategies to assist with adherence should be incorporated into the care of all transplant patients. Based on survey data, however, only about half of US transplant centers have protocols to evaluate adherence.⁵ When attempts are made to increase adherence, the most commonly used intervention is providing reading materials, which has not been found to be effective when used in isolation.⁶

Currently, there are no guidelines outlining best practice interventions that can be used by transplant centers to increase adherence after transplant. In 2015, members of American Society of Transplantation's Psychosocial Community of Practice, with representatives from the Transplant Pharmacy Community of Practice, convened a task force to develop recommendations for clinically practical, evidence-based interventions that transplant centers could implement to improve patient adherence to medications, healthcare provider visits, and lifestyle recommendations in adult organ transplant recipients. Focusing on items that clinicians could implement in their daily routines to increase and maintain patient adherence, we developed a list of strategies that includes existing resources and clinically

feasible methods of screening and tracking adherence. We focused on adult organ recipients as this is the primary population studied, and because adherence issues and interventions in pediatric patients differ. We examined interventions based on patient, provider and transplant program practices because adherence is influenced by multiple factors. We did not include policy-level systemic solutions (ie, better coverage of medication costs through long-term Medicare immunosuppression coverage), as these interventions would not be within the direct control of the transplant center. Given the existence of other comprehensive reviews on adherence in transplant patients,⁴ we focused on issues related to feasibility for clinical application, scalability, and dissemination. We identified the key findings from the literature and then came to consensus about best practices for adherence assessment and intervention.

2 | RISK FACTORS FOR NONADHERENCE

Research has identified numerous modifiable and nonmodifiable factors that play a role in the risk of nonadherence among solid organ transplant recipients, pre-and post-transplant (Table 1). Risk factors are often inconsistently associated with nonadherence;^{2,4,7} and the ability of specific risk factors to predict nonadherence varies by the adherence behavior that is being studied (eg, medication adherence vs other adherence behaviors). Therefore, we propose early identification (pretransplant) of potential risk factors and barriers to allow for targeted intervention and heightened monitoring. When warranted, pretransplant psychosocial and adherence evaluation may allow pretransplant interventions to be performed to mitigate post-transplant nonadherence. Once risk factors and barriers to adherence are identified, interventions to promote adherence should be implemented throughout the transplant process.

3 | TOOLS TO ASSESS NONADHERENCE

Previous reviews have identified numerous ways to measure adherence.⁸ Although multimodal adherence assessment is recommended,⁸ and it may be synergistic to use 2–3 methods simultaneously, this approach may not be practical or even possible in routine clinical practice often due to cost, time, or staffing constraints. The top priorities of adherence screening in a clinical setting are to detect nonadherence, implement interventions, then track progress over time. The objective for selecting an adherence measure should be to balance reliability and validity with practicability for administration. Table 2 details the strengths and weaknesses of common approaches, along with recommendations for their use.

Perhaps the most expedient and efficient means of screening for adherence at a low cost in a clinical setting is patient self-report through standardized survey instruments.⁹ Several transplant-specific⁸ instruments are available for use with transplant patients which have demonstrated reliability and validity, (reviewed in detail by Dobbels et al.⁹). These measures are brief and can be administered informally during the course of clinical interviews or counseling. Some instruments cover only medication adherence,⁹ but others cover the entire range of medical recommendations following transplant, including attending clinic visits, completing required labs and medical tests, and dietary and exercise requirements.⁸ Another advantage of self-reported adherence measures is their ability to elicit potential reasons for

Disadvantages to patient self-report include lower specificity, sensitivity, and precision about the extent of nonadherence, and the potential for reporting bias due to either poor recall or an interest in giving the healthcare provider the desired response.¹⁰ However, a meta-analysis² showed that self-report assessments captured higher rates of nonadherence to immunosuppressants than other assessment methods. In addition, they may be superior to other measures of assessing nonadherence because they are less expensive and labor intensive, and more practical in clinical settings compared to other methods. Disadvantages of self-reports may be minimized if they are administered in a nonjudgmental way and conservative cut-offs are chosen to define nonadherence to reduce bias from under-reporting nonadherence.⁹

The strengths and weaknesses of other methods, including provider reports, medication refill reports, medication blood level metrics, electronic medication event monitoring devices, remote spirometry for lung transplantation, and other biological assays are detailed in Table 2. Due to underestimation, we do not recommend the sole use of provider reports of nonadherence.¹¹ Although providers are encouraged to conduct standardized reviews of medical records to examine patients' adherence to laboratories and clinic visits, multimodal methods of nonadherence assessment are more sensitive.¹¹ Similarly, although there are some attractive properties of medication refill reports, electronic medication event monitoring devices, and assays of medication levels in patients' blood, there are also potentially prohibitive disadvantages including availability of resources to obtain medication refill reports and access to electronic medications event monitoring devices.¹¹ Despite these concerns, electronic monitoring devices can provide detailed data on medication-taking initiation, execution, and persistence, which are key components for identifying opportunities for interventions.

4 | BEST PR ACTICES FOR INTERVENTIONS

In Table 3, we summarize interventions that have been tested and found efficacious, their key components, implementation benefits, challenges, and other considerations. Transplant centers with diverse needs, patient populations, and resources for adherence monitoring and interventions may need to tailor the implementation of these efforts in different ways, and it is likely that no "one-size-fits-all" approach is warranted to recommend to all transplant centers.

4.1 | Educational intervention

Education is the most frequently used method by transplant staff to encourage patient adherence.⁶ Education is often necessary to ensure patients' understanding of their condition and treatment. Transplant patients and their supports report the need for comprehensive education related to transplantation.⁶ The duration and content of educational interventions range from brief and general (eg, providing an educational brochure) to repeated and individualized. Although they have been shown to improve patient understanding and knowledge, meta-analytic data show that education alone does not significantly impact

adherence.¹² Therefore, we recommend that education should be paired with other empirically supported adherence interventions. Also, it should be provided throughout all transplant phases as patient needs change over time from pretransplant, inpatient, early and late post-transplant. Education should be provided via a multidisciplinary approach that could include a coordinator, social worker, psychologist, and/or pharmacist based on available resources.

4.2 | Cognitive/behavioral interventions

Interventions aimed at improving adherence through repeated visits with transplant team members and/or through implementing memory or monitoring strategies may be characterized as cognitive/behavioral interventions.⁴ Many of these interventions involve discussions regarding patients' motivation for adherence, involvement of social support, addressing barriers to adherence, and implementing strategies to enhance adherence, such as assistive tools (eg, alarm, a pill box) or receiving reminders from others.⁴,13

Behavioral contracts have been used before and after transplant to increase adherence with medication and other behaviors.¹⁴ In behavioral contracting, the patient and a provider identify a specific health behavior to address, then write an agreement (the contract) describing how the behavior will be modified to achieve the desired effect.¹⁴ Contracting is designed to increase patients' sense of self-efficacy, or belief in their ability to accomplish a goal, which is correlated with medication-taking in transplant patients. Behavioral contracts can be an effective method of delineating expectations about post-transplant adherence while holding patients accountable for their actions. However, contracting may require extra effort and time by a member of the transplant team.¹⁴

Pharmacist counseling is the addition of multiple visits with pharmacists to individualize pharmaceutical care after transplant and has been found to be successful in improving medication adherence.¹⁵ Because the pharmacist can identify patients who may require intervention early,¹⁶ the intervention may start at the pretransplant evaluation phase or the initial hospitalization after transplant surgery and continue post-transplant.¹⁷ The pharmacist's role entails education about medications, and uses a collaborative approach to identify signs of nonadherence and barriers that may increase the risk of nonadherence in the future, such as side effects, cost, and regimen complexity, and includes review of medication regimens, laboratory values, and side effects. The pharmacist can modify medication regimens to reduce adverse effects or select lower cost alternatives.¹⁵

Motivational interviewing (MI) is a nonjudgmental style of communication that helps patients to elicit their own intrinsic desire and intent to change behavior.¹⁸ Because multiple motivations can be at play when it comes to following a medical regimen, this can be a particularly effective strategy. MI interventions improve adherence to medication and lifestyle recommendations in patients with chronic disease,¹⁹ but only one study used MI in transplant to date.²⁰ MI requires clinician training to ensure proper implementation. This may be a barrier in some transplant settings, as the cost and time for training team members in MI may be prohibitive. However, some centers may already have social workers, psychologists, psychiatrists, or pharmacists trained in this technique.¹⁹ Thus, we recommend

that transplant teams explore the trade-offs between the intensity of training required and resources available to support the training, versus the benefits to patient outcomes.

In summary, advantages of cognitive/behavioral interventions include the personalized nature of these interventions, with time spent understanding the patients' perspectives and their individual barriers to adherence. These interventions can be tailored over time to meet patients' needs. Through these interventions, patients become more active, empowered participants in their medical care, and communication between patients and their transplant team is increased.¹⁴ Disadvantages of these interventions include their potentially time-consuming and personnel-intensive nature. Transplant centers may not have the number of staff needed to maintain frequent patient visits and monitoring. Many of the studies examining these strategies for improving adherence have only tested them over short time periods; thus, the long-term feasibility of implementing them is still unknown.

4.3 | Health information technology intervention strategies

Health information technology (HIT) applications are used increasingly often by both healthcare professionals and patients. HIT applications include traditional software run on desktop and laptop computers, Internet-based strategies, personal electronic monitoring devices that track routine daily behaviors (eg, fitness devices), and smartphone apps. The ubiquity and widespread acceptance of apps by all types of users suggest that they may be prime strategies for transplant programs to harness and facilitate patient adherence.²¹ Within organ transplantation, studies have begun to examine the efficacy of some HIT approaches.²¹ This work is summarized below and leads to our suggestions in Table 3 regarding potential benefits and challenges for transplant programs to consider if they seek to use any of four HIT approaches to improve or maximize patients' medical adherence.

A notable example of a *smartphone app* that has undergone user-centered development and testing in transplant recipients is the Pocket Personal Assistant for Tracking Health (Pocket PATH). Tailored to the specific elements of the post-transplant medical regimen,²² it includes customized data recording and graphing programs for tracking health indicators, activities, and symptoms; reminders about medication-taking and other behaviors; and decision support to guide patients about when to seek assistance from the transplant team. In a randomized controlled trial, Pocket PATH users showed better self-monitoring and adherence.²²A critical element of effective apps is that they include multiple components; single-component apps, (eg, those providing only educational information) do not appear useful.²¹ Useful websites that discuss and compare available apps are https:// publichealthonline.gwu.edu/quantified-self-health-tracking-technology/ and www.medappfinder.com, and several reviews of commercially available apps for general health behavior and adherence to medication specifically have been published in recent vears.²¹ Reviews conclude that an increasing number of patients have access, are willing to use, and are highly satisfied with smartphone apps, but that interest in using an app decreases over time.21

Websites for patient health promotion and medical regimen adherence have been found effective in various chronic disease populations.²³ Many transplant programs now host their own webpages, either within the websites of their home institutions or through other sources

(eg, Facebook). Although often focused on educational information, programs could consider including other features found useful in chronic disease and transplant populations, including bulletin boards for (nonurgent) patient questions and comments, opportunities for patients to upload personal data to monitor trends over time, and interactive workshops. These features may benefit patients and be time-saving for programs, such as face-to-face education, obtaining more detailed information, skills-building activities, or tools to monitor self-care activities. However, resources would be needed to ensure that materials were updated regularly and that patients' posted comments or questions were appropriate and not about urgent issues.

Providing patients with *prompts, alerts, or reminders* to take medications or perform other activities also improves medical regimen adherence.¹³ Studies of medication taking suggest that monitoring systems that include multiple components (eg, reminders emitted by medication dispensers combined with smartphone app reminders, tracking capabilities, and text messaging) are more likely to promote adherence²⁴ than are simple medication dispensers with alerts or alarms used in isolation.²⁵ However, the studies in transplant recipients have followed patients for relatively short periods of time (a year or less),^{24,25} and the long-term durability of any effects is unknown.

Remote monitoring of other health activities (eg, blood pressure monitoring, glucose monitoring, home spirometry) can also facilitate patient adherence in transplant patients.²⁶ Finkelstein and colleagues demonstrated that home monitoring and transmission of pulmonary function results to the transplant team by lung recipients is feasible, allows for timely interpretation by the transplant team, and can be facilitated by computer-based algorithms that assist transplant team members in determining when patients require clinical intervention.²⁶ Many medical centers are expanding their use of telemedicine and may have their own remote monitoring and alerting systems that could be adopted by their transplant programs to address specific patient self-management issues.

Text messaging has generally superseded the use of other rapid electronic communications (eg, pagers, beepers) for immediate communication with patients. A recent meta-analysis found that mobile phone text messaging more than doubled the likelihood of patient medication adherence, across studies of chronic disease populations.²⁷ Although this report did not identify any studies focused on transplant patients, the findings strongly suggest that text messaging may be similarly useful with transplant recipients, and text messages have been incorporated into a recent multicomponent intervention tested with kidney recipients.²⁴ Text messaging is the least complex and costly of the HIT interventions discussed and may be highly feasible for most transplant programs to implement and routinely use.

5 | CONCLUSIONS AND RECOMMENDATIONS

Although we have emphasized the costs and limitations of measuring, monitoring, and intervening upon nonadherence, it is also important to emphasize the profound cost to health, quality of life, payers, and society of not doing so. Thus, our group hopes that this article will be a call to action for centers and health systems to re-evaluate their cost equations, to incorporate the approaches discussed. As acknowledged in our introduction,

our group hopes that a similar initiative develops for pediatric/adolescent transplant recipients. Tables 1–3 are designed to allow readers to easily select methods to systematize screening for risk factors, assess and monitor adherence, and intervene on patients at risk for nonadherence that best meet the needs of their patients within the existing assets of their unique transplant center. Our overall recommendations are summarized in Table 4. Other specific recommendations may be found in the work of Oberlin and colleagues, who developed a model that includes five strategies for transplant centers to incorporate evidence-based interventions into their clinical care activities;²⁸ or by the COMMIT Group, who developed a guidance report and clinical checklist on managing modifiable risk in transplantation.³

Coupled with patient report of nonadherence, technology-based nonadherence monitoring may complement technology-based nonadherence interventions with transplant recipients and offer accurate, but clinically feasible, screening for nonadherence in a way that not only detects nonadherence, but also reveals the reasons for nonadherence. To achieve these multiple objectives, we recommend patient reports using validated, standardized instruments for nonadherence screening. The coupling of screening with more intensive intervention approaches is likely the most effective way to increase adherence among transplant patients. Educational interventions are important to adherence; however, they should be coupled with other interventional components, such as behavioral contracting, clinical, counseling, and motivational interviewing. Given that adherence is known to decline over time posttransplant, it is important for transplant teams and patients to stay engaged in these strategies over the long-term. Additionally, incorporating technology-based methods, such as text messaging and smartphone, computer, or tablet applications can improve adherence. Although it may be time- and resource-intensive to expand interventions beyond patient education, we strongly recommend providers consider these additional investments.

Transplant teams can use models such as the Model for Improvement²⁹ or the Consolidated Framework for Implementation Research (CFIR) Model³⁰ to implement and reliably test these strategies. Finally, for any adherence measurement, tracking and intervention effort to be effective, the entire team would need to support its' use. If such activities are seen as the sole responsibility of only one team member, it is likely that both patients and the team as a whole will continue to see the activities as peripheral rather than central to patient care.

Funding Information

Work on this paper was supported by NIDDK, Grant/Award Number: #R01DK101715 and Dialysis Clinic Inc. (DCI) - a national non-profit corporation.

REFERENCES

- 1. Sabaté E. Adherence to long-term therapies: evidence for action. Geneva, Switzerland: World Health Organization; 2003.
- Dew MA, DiMartini AF, De Vito Dabbs A, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation. 2007;83(7):858–873. [PubMed: 17460556]
- 3. Neuberger J, Bechstein W, Kuypers D, et al. Practical recommendations for long-term management of modifiable risks in kidney and liver transplant recipients: a guidance report and clinical checklist

- Dew MA, Posluszny DM, DiMartini AF, Myaskovsky L, Steel JL, DeVito Dabbs AJ. Posttransplant medical adherence: what have we learned and can we do better? Curr Transplant Rep. 2018;5:174– 188. e-pub ahead of print. [PubMed: 30416933]
- Brar A, Babakhani A, Salifu MO, Jindal RM. Evaluation of non-adherence in patients undergoing dialysis and kidney transplantation: United States transplantation practice patterns survey. Transpl Proc. 2014;46(5):1340–1346.
- Berben L, Dobbels F, Kugler C, Russell CL, De Geest S. Interventions used by health care professionals to enhance medication adherence in transplant patients: A survey of current clinical practice. Prog Transplant 2011;21(4):322–331. [PubMed: 22548995]
- Tong A, Howell M, Wong G, Webster A, Howard K, Craig J. The perspectives of kidney transplant recipients on medicine taking: a systematic review of qualitative studies. Nephrol Dial Transplant. 2011;26(1):344–354. [PubMed: 20584734]
- Hansen RA, Kim MM, Song L, Tu W, Wu J, Murray MD. Comparison of methods to assess medication adherence and classify nonadherence. Ann Pharmacother. 2009;43(3):413–422. [PubMed: 19261962]
- Dobbels F, Berben L, De Geest S, et al. The psychometric properties and practicability of self-report instruments to identify medication nonadherence in adult transplant patients: a systematic review. Transplantation. 2010;90(2):205–219. [PubMed: 20531073]
- 10. Lam WY, Fresco P. Medication adherence measures: an overview. Biomed Res Int. 2015;2015:12.
- Butler J, Peveler R, Roderick P, Horne R, Mason J. Measuring compliance with drug regimens after renal transplantation: comparison of self-report and clinician rating with electronic monitoring. Transplantation. 2004;77(5):786–789. [PubMed: 15021850]
- Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. Arch Intern Med. 2007;167(6):540–549. [PubMed: 17389285]
- Conn V, Ruppar T, Enriquez M, Cooper P. Medication adherence interventions that target subjects with adherence problems: systematic review and meta-analysis. Res Soc Admin Pharm. 2016;12(2):218–246.
- Chisholm-Burns M, Spivey C, Graff ZJ, Lee J, Sredzinksi E, Tolley E. Improving outcomes of renal transplant recipients with behavioral adherence contracts. Am J Transplant. 2013;13(9): 2364–2373. [PubMed: 23819827]
- Chisholm-Burns M, Spivey C, Sredzinski E, Butler S. Intervention toolbox to promote immunosuppressant therapy adherence in adult renal transplant recipients. J Am Pharm Assoc. 2012;52(6):816–822.
- Dobbels F, Vanhaecke J, Dupont L, et al. Pretransplant predictors of posttransplant adherence and clinical outcome: an evidence base for pretransplant psychosocial screening. Transplantation. 2009;87(10):1497–1504. [PubMed: 19461486]
- Taber D, Pilch N, Trofe-Clark J, Kaiser T. A national survey assessing the current workforce of transplant pharmacists across accredited U.S. solid organ transplant programs. Am J Transplant 2015;15(10):2683–2690. [PubMed: 25988533]
- Miller WR, Rollnick S. Motivational Interviewing: helping People Change (3rd Edition). New York, NY: The Guilford Press; 2013.
- Zomahoun H, Guénette L, Grégoire J, et al. Effectiveness of motivational interviewing interventions on medication adherence in adults with chronic diseases: a systematic review and meta-analysis. Int J Epidemiol. 2017;46(2):589–602. [PubMed: 27864410]
- Dobbels F, De Bleser L, Berben L, et al. Testing the efficacy of a multicomponent theory-based tailored behavioral medication adherence intervention in transplantation: the MAESTRO-TX RCT. J Heart Lung Transplant. 2016;35(4-Supplement):S90.
- 21. Fleming J, Taber D, McEllligott J, McGillicuddy J, Treiber F. Mobile health in solid organ transplant: the time is now. Am J Transplant. 2017;17:2263–2276. [PubMed: 28188681]
- DeVito Dabbs A, Song M, Myers B, et al. A randomized controlled trial of a mobile health intervention to promote self-management after lung transplantation. Am J Transplant. 2016;16(7): 2172–2180. [PubMed: 26729617]

- 23. Krebs P, Prochaska J, Rossi J. A meta-analysis of computer-tailored interventions for health behavior change. Prev Med. 2010;51:214–221. [PubMed: 20558196]
- Reese P, Bloom R, Trofe-Clark J, et al. Automated reminders and physician notification to promote immunosuppression adherence among kidney transplant recipients: a randomized trial. Am J Kidney Dis. 2017;69(3):400–409. [PubMed: 27940063]
- 25. Henriksson J, Tyden G, Hoijer J, Wadstrom J. A prospective randomized trial on the effect of using an electronic monitoring drug dispensing device to improve adherence and compliance. Transplantation. 2016;100:203–209. [PubMed: 26588006]
- 26. Finkelstein S, Lindgren B, Robiner W, et al. A randomized controlled trial comparing health and quality of life of lung transplant recipients following nurse and computer-based triage utilizing home spirometry monitoring. Telemed e-Health. 2013;19(12):897–903.
- 27. Thakkar J, Kurup R, Laba T, et al. Telephone text messaging for medication adherence in chronic disease: a meta-analysis. JAMA Intern Med. 2016;176(3):340–349. [PubMed: 26831740]
- Oberlin S, Parente S, Pruett T. Improving medication adherence among kidney transplant recipients: Findings from other industries, patient engagement, and behavioral economics—a scoping review. Sage Open Med. 2016;4:2050312115625026. [PubMed: 26835016]
- 29. Langley G, Moen R, Nolan K, Nolan T, Norman C, Provost L. The Improvement Guide: a Practical Approach to Enhancing Organizational Performance (2nd Edition). San Francisco, Ca: Jossey-Bass Publishers; 2009.
- Damschroder LJ, Aron DC, Keith RE, Kirsh SR, Alexander JA, Lowery JC. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. Implement Sci. 2009;4:50. [PubMed: 19664226]
- Dew MA, DiMartini AF, De Vito Dabbs A, Myakovsky L, Steel J, Unruh M, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation. 2007;83:858–873. [PubMed: 17460556]

Myaskovsky et al.

| M | Modifiable | | Nonmodifiable | able |
|--|------------|---|---------------|----------------------------------|
| Sociodemographics ^{4,7,16,31} | | | • | Younger age |
| | | | • | Male gender |
| | | | • | Race/ethnicity |
| | | | • | Lower SES |
| | | | • | Rural (versus urban) residence |
| | | | • | Living alone |
| Pretransplant factors ^{4,7,16,31} | • | Adherence (pre-tx) | • | More comorbid medical conditions |
| | • | Reduced medication self-efficacy ^a | | |
| | • | Mood disorder/depression | | |
| | • | Anxiety | | |
| | • | Hostility | | |
| | • | Limited social support/lower perceived social support | | |
| | • | Lower conscientiousness | | |
| | • | Health literacy | | |
| Post-transplant factors ^{4,7,16,31} | • | Distress | • | Longer time since transplant |
| | • | Depression | | |
| | • | Low self-care agency b | | |
| | • | Disruption to daily routine/travel | | |
| | • | Forgetfulness | | |
| | • | Poorer perceived health | | |
| | • | Running out of medication | | |
| | • | Inadequate monetary funds to cover medication costs | | |
| | • | Low knowledge/negative beliefs about medications | | |
| | • | Medication complexity (type and schedule) | | |
| | | Madination afforts | | |

^aSelf-efficacy—an individual's belief that he or she has the ability to implement a behavior that will produce a desired outcome.

script Author Manuscript

b Self-care agency—an individual's cognitive and physical/behavioral ability to engage in self-care, this includes the ability to perform behaviors aimed at maintaining health and well-being.

Myaskovsky et al.

| | | Recommendation | We recommend use of a self (patient)- reported standardized instrument that indicates reasons for nonadherence (eg, intentional or unintentional). Efforts should be made to reduce bias in reporting, such as explaining to the patient that it may be difficult to stay totally adherent to all prescribed regimen components | We do not recommend the sole use of provider reports | We recommend use of refill reports if a clinic has resources in place to access these metrics | We recommend use of blood levels if a clinic has resources in place to collect blood samples and data | Recommended if a clinic has resources in place to purchase and implement these devices | We recommend that this method should be implemented for laboratory tests and clinic visits | We recommend this method as a complement to patient report if a clinic has resources to commit to its use |
|---------|--|--------------------|---|---|--|---|--|---|---|
| TABLE 2 | | Weaknesses | May be less sensitive, specific, or precise than desired, subject to desirability response bias and recall bias; in the case of medication adherence, does not assess key components of medication-taking execution, for example taking, timing, or drug holidays | May be less sensitive, specific, or precise than desired, subject to bias due provider misperceptions; often underestimates nonadherence; in the case of medication adherence, does not assess key components of medication-taking execution, for example taking, timing, or drug holidays | Indirect measure—pills obtained by patients may not have been taken, not taken on time, and/or not taken for multiple days (ie, drug holiday), clinics may not have access to all pharmacies used by their patients to obtain refill records, may not reflect dose changes | Potentially difficult or expensive to implement, relatively intrusive to patient; only reflects adherence within a few days prior to level (ie, skipped for multiple days drug holiday); potentially less accurate because many factors other than adherence impact blood level results | Expensive to obtain, potentially difficult and costly to implement by providers and use by patients, indirect measure—pills removed from device by patient may not have been taken; patients often only willing to use for short periods of time and do not see these devices as suitable replacements for weekly pill boxes for all medications | Requires access to electronic medical record | Potentially difficult to implement by providers and for use by patients, indirect measure |
| | ring adherence for clinicians | Strengths | Inexpensive, easy to administer, can determine reasons for nonadherence and lead to intervention planning, represents patients' experience/views; can assess multiple elements of the posttransplant medication regimen, including medication-taking, clinic appointment attendance, completion of blood work, use of substances (eg, alcohol, tobacco), and any other monitoring requirements, (eg, blood pressure, temperature, lung function) | Inexpensive, easy to administer, can determine reasons for nonadherence and lead to intervention planning | Not subject to reporting bias, potentially accurate, potentially inexpensive | Direct measure of whether medication has been taken | Can provide precise determination of concordance between pills used and prescribed regimen (eg. taking, timing, durg holidays), continuously records pill usage over desired time period and can quantify length of gaps between pills used, not subject to reporting bias | Can provide data on appointment and laboratory testing adherence; easily accessible by transplant staff; adherence assessment can be performed quickly | Can provide precise determination of spirometry use; not subject to reporting bias |
| | Comparison of approaches to measuring adherence for clinicians | Measurement method | Self-report w/standardized instruments | Provider report | Medication refill reports ^a | Medication blood levels ^a | Electronic medication event monitoring devices ^a | Electronic medical record review of adherence behavior (eg, clinic appointments, laboratories completed) | Remote spirometry monitoring (in lung transplantation) |

Author Manuscript

Author Manuscript

Author Manuscript

Measurement method

Direct measure of whether prohibited substances have been used

Potentially difficult or expensive to implement, relatively intrusive to patient

Myaskovsky et al.

We recommend this method as a complement to patient report if a clinic has resources to commit to its use

Recommendation

^aOnly applicable to medication adherence.

| | Other considerations | Should supplement other strategies; not other strategies; not effective in isolation her Benefits may be sustained longer if social supports are engaged I staff | | Contract meetings may be conducted in- person or over the telerhouse | • | | Provides opportunity for providers to simplify the medication regimen; address side effects; or, address drug availability or financial barriers |
|---|--------------------------------------|--|------------------------------------|--|---|--|--|
| | 6 | Patient recall of information may reduce over time, especially when receiving other information about transplant Requires some level of literacy and fluency in language the information is provided Requires dedicated staff time and training | | Could be time- consuming for provider Patient may have | difficulty implementing tools/strategies to improve adherence. In this case, the provider should be available to assist or guide the patient as needed | | Could be time- consuming for provider |
| tions | Challenges | | | • • | | | |
| ges and other considera | | Majority of patients and support persons want comprehensive education Can be offered in various patient languages, literacy level, and specific to individual situations | | Specific to the individual patient Promotes | communication between patient and provider Facilitates opportunities for providers to educate patients and reinforce importance of adherence | | Facilitates an individual approach to removing barriers to medication- taking and reinforces importance of adherence |
| s, challen | Benefits | · · | | • • | | | • |
| plementation benefits | nents | Oral, written, auditory, or audio-visual formats Provision to individuals or groups | | Regular meetings with provider to renew/ renegotiate contract | Contract components include: goals, motivations, consequences of nonadherence, social support, adherence reminders, barriers to adherence, and tools to overcome barriers | Both provider and patient sign contract to reinforce commitment to achieving adherence goals | Scheduled meetings with a pharmacist to review medication history, current medication regimen (including dosage schedule and special instructions for taking medication), side |
| ts, and im | Key components | | | • | • | • | • |
| Interventions, key components, and implementation benefits, challenges and other considerations | Intervention strategies Education | | Cognitive behavioral interventions | Behavioral contracting | | | Pharmacy counseling |

Author Manuscript

Author Manuscript

Author Manuscript

TABLE 3

Author Manuscript

Author Manuscript

Other considerations

Challenges

| Key components | Benefits | |
|---|----------|--|
| effects, and laboratory values | | |
| Collaborative | • | Patient-centered: |
| approach used to identify barriers to | | patients partner/ collaborate with |
| adherence and to implement | | providers throughout the intervention process |
| intervention goals through exploring the | • | Promotes communication between |
| development of a plan | | patient and provider |
| of action to support adherence | • | May assist patient in addressing ambivalence |
| | | regarding adherence to |

Motivational interviewing

Intervention strategies

long-term medication regimen

Apps may be Good patient acceptability

Software downloaded

Health information technology

Smartphone or tablet apps

patients visualize trends inexpensive or free Components help and be alerted to

trends in symptoms or

components to graph behaviors over time

May include onto device

May include alerting/

reminder functions May include educational information

potential problems in

Mobile health apps have been judged by governmental agencies such as the FDA to pose real time

low risks to patients

one, in group sessions, or over the telephone interviewing may be conducted one-on-Motivational • Need to assess fidelity to Must be conducted by a performing motivational Duration of intervention nonadherence have not interviewing protocol received training in transplant patients provider who has been assessed in and impact on interviewing motivational

Use may be limited by patient vision, dexterity, literacy, or health

Patient use may decline

over time

familiarity with the app to advise patients Transplant program staff would need on use

> Patients may not have resources to purchase

literacy

use apps (eg, providing feedback on patients motivated to Strategies may be needed to keep app results)

•

may not have resources

to develop apps;

Transplant programs

electronics or apps

available apps may not have desired features Apps tested in research available; commercial

used to address urgent understand that the apps should not be or time-sensitive health issues Patients must

apps may not have been tested for efficacy

transmitted from device

Any data to be

program would need

security and confidentiality

protections

to the transplant

•

may not be publicly

| Author Manuscript | |
|-------------------|--|
| Au | |

| ~ |
|------------|
| <u> </u> |
| -t |
| |
| = |
| 0 |
| - |
| - |
| ~ |
| < |
| |
| ω |
| = |
| <u> </u> |
| |
| - |
| S |
| õ |
| \odot |
| _ . |
| |
| 0 |
| |
| |

| Other considerations | Similar constraints as noted above with apps: • See other considerations for considerations for apps; these apply for program development, websites as well and security/ and security/ • If development hyper and security/ | connoentatity challenges as for apps challenges as for apps Websites may lack feel would be useful feel would be useful Websites tested in Websites tested in transplant program, resources would be needed to update and monitor website feel would be useful website steed in | e blicly have cacy | It may be inconvenient transpiant programs to access the Internet in monitor and respond public locations and in a timely way to patients may be unable posted comments to afford either a | computer or Internet access | | May require purchase of • Same issues are for monitoring equipment; apps and data transmission costs | Patients may be unable to afford or unwilling to purchase these systems | Similar declining use, vision, manual dexterity, literacy, security issues as for apps | Systems tested in research may not be available, those commercially available may nor have been |
|-------------------------|--|--|--|--|---|--|--|---|---|---|
| Challenges | | | | • | | | | | • | • |
| | Good patient acceptability Use may be inexpensive or free | If hosted by a transplant program, program can ensure accurate content; patients may feel more connected to the program | Patients may feel more connected to other patients with similar health conditions | May be time-saving for transplant programs; patients can be referred to website for information/resources | Users need not own any device: Internet can be accessed at public locations, e.g., libraries | If desktop/laptop computer is used, vision and manual dexterity problems may be minimized due to keyboard/screen size | Alerting/reminder systems can lessen patients' need to remember to perform activities | Remote monitoring can provide information to the transplant team in | real units Remote monitoring can reduce the need for patient to return to | frequent monitoring Commercially available remote monitoring |
| Benefits | | • | • | • | • | • | • | • | • | |
| nents | Available via the Internet using multiple devices (personal computers, tablets, smartphones) | May include multiple components (eg, education, communication with other users or experts, options for uploading | personal data to monitor health trends or activities) | | | | Usually requires that patients receive a device and maintain it in their homes (eg, a special medication | uispenser or equipment for monitoring health parameters) | May include or require Internet access or other technology for transmitting data | May include alerting features to remind patients or notify them of problematic values |
| Key components | • | • | | | | | • | | • | • |
| Intervention strategies | Websites | | | | | | Alerting and remote monitoring systems | | | |

Author Manuscript

| Myaskovsky et al. | |
|--------------------|--|
| wiyaskovsky et al. | |

| Intervention strategies | Key components | Benefits | Challenges | sag | Other considerations | iderations |
|---|--|----------|---|--|----------------------|--|
| | | | systems have often been extensively tested | friendliness;" patients may require assistance in setting up the systems | | |
| Text messaging | Transplant team or automated system | • | Good patient acceptability | Similar declining use, literacy, vision, | • | Policies would need to be in place for |
| | contacts patients on cell phone to remind them about clinic visits amédical | • | Does not require a smartphone; other mobile phone devices | confidentiality issues as for other technologies | | whether the text messaging is one way only (from program to natient) or whether |
| | appointments, labs that are due, etc. | | can receive these messages | Requires that patients have cell phone; some | | program would encourage/allow |
| | Contact can require a response by the patient indicating task has | • | If automated, can be time-saving for transplant program | to afford cell phones | • | pattents to send text messages as well Strategies may be |
| | been accomplished | • | Potentially less intrusive than phone calls and answering machine messages | | | needed to keep patients motivated to act when they receive text messages |
| | | • | Potentially more confidential than communication by pagers or beepers | | | |
| Nurses refers to either nurse coordinators or floor nurses. | tors or floor nurses. | | | | | |

TABLE 4

Summary of recommendations for adherence intervention and monitoring

Use validated adherence screening tools. If possible, use a multimodal approach to assessing adherence (eg, patient report + pharmacy records or electronic monitoring + screening for missed appointment and labs) Use technology-based interventions and adherence monitoring approaches Recommendation 1: Recommendation 2:

Recommendation 3: Couple educational interventions with other intervention approaches (eg, behavioral, cognitive)

Include the entire transplant team (including the surgeons, psychologist, psychiatrist, pharmacist, and social worker) in adherence monitoring and intervention implementation Recommendation 4: